Pricing Log in Create free account
Tuesday 13 October 2026 Export ENTX’s income statement to Excel — free account

Entera Bio Ltd.

ENTX Healthcare Biotechnology

Entera Bio Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42,000.00, down 76.8% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS fell 133.3% and free cash flow fell 108.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.47 0.18 −6.79%
Market cap
$460.7M
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
n/a
Altman Z
6.22
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.14
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — 1 — 5 2 — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 460.66
Revenue 0.22
Net Income (17.03)
Free Cash Flow (10.99)
Net Debt (18.43)
Current Ratio 8.98 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (3.47) (negative: loss-making)
P/S ratio 599.53 (above 10: high)
P/B ratio 18.40 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth (67.00%) (below 0%: weak)
Next Y EPS Growth 8.38%
Next Y revenue growth 0.00%
Next 5Y EPS Growth (17.20%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 534×, against a ten-year median of 138×; over the ten years it ranged from 20.0× in 2019 to 611× in 2026.
P/S against its own 10 years 93.43%
10-year low 10-year high
P/B against its own 10 years 97.39%
10-year low 10-year high
EV/Sales against its own 10 years 91.73%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 11 9 15 18
Receivables — 0 — —
Inventory — — — —
Other 0 0 0 0
11 9 15 19
2023 2024 2025 Q'26
Payables 0 0 0 1
ST’ Debt — — — —
Other — — — —
1 1 2 2

Compound Annual Growth %

10y 5y 3y
Sales — (29.19%) (58.10%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 11.77% 3.68%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 0 — — — 0
’24 — 0 0 0 0
’22 0 0 0 0 0
’21 0 0 0 0 1
’20 0 0 0 0 0
’19 — 0 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (1) (2) (3) (2) (7)
’24 (2) (1) (2) (1) (7)
’23 (2) (2) (2) (3) (7)
’22 (5) (3) (3) (2) (12)
’21 (2) (2) (2) (3) (9)
’20 (3) (4) (3) (2) (11)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (1) (2) (3) (2) (7)
’24 (2) (1) (2) (1) (7)
’23 (2) (2) (2) (3) (7)
’22 (5) (3) (3) (2) (13)
’21 (2) (2) (2) (3) (9)
’20 (3) (4) (3) (2) (11)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — (0.07) —
’24 (0.05) (0.06) — (0.06) —
’23 (0.08) (0.08) (0.08) (0.07) —
’22 (0.13) (0.11) (0.11) (0.10) (0.45)
’21 (0.10) (0.10) (0.11) (0.15) (0.47)
’20 (0.16) (0.17) (0.09) (0.18) (0.55)
Fiscal quarters ending in the months shown.
value withheld pending a data check

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — 2.78 1.35 1.00 1.07 0.47 0.52 0.58 1.50

Analyst estimates 2026–2028

Powerpack
High — — 7.60 5.10 3.40 10.16 3.51 1.48 3.35 3.22
People
People Employees — 19 19 26 18 27 20 19 20 22
Revenue/emp, $m — 0.00 0.03 0.01 0.02 0.02 0.01 0.00 0.01 0.00
Income, $m
Income, $m Revenue — — 1 0 0 1 0 — 0 0
Gross margin, % 0.00 0.00 100.00 11.02 17.81 34.68 24.63 — 4.97 0.00
EBT (1) (11) (10) (11) (11) (12) (13) (9) (10) (11)
EBT margin, % 0.00 0.00 (2,060.80) (4,574.15) (3,067.40) (2,144.66) (9,652.24) 0.00 (5,263.54) (27,235.71)
Net income (1) (11) (10) (11) (11) (12) (13) (9) (10) (11)
Depreciation — 0 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue 0.00 0.00 0.06 0.02 0.02 0.02 0.00 0.00 0.00 0.00
Earnings (0.10) (2.49) (1.30) (0.89) (0.54) (0.47) (0.45) (0.31) (0.25) (0.25)
Cash flow (0.27) (1.01) (1.23) (0.73) (0.57) (0.35) (0.43) (0.25) (0.18) (0.16)
Capex 0.00 (0.01) (0.01) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Free cash flow (0.27) (1.02) (1.24) (0.74) (0.58) (0.35) (0.44) (0.25) (0.18) (0.16)
Book value (2.17) (7.03) 1.27 0.98 0.41 0.86 0.41 0.36 0.21 0.28
Shares, m 12 4 8 12 18 26 29 29 38 46
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00
P/S — — 0.00 35.32 54.49 129.07 219.28 — 409.32 401.84
P/B — — 4.73 2.18 2.65 3.27 2.50 — 9.88 6.84
EV/Sales — — 0.00 19.98 41.62 92.29 156.48 — 384.88 352.56
EV/FCF — — (4.08) (1.64) (1.43) (5.79) (1.67) — (10.99) (10.51)
Cash, $m
Cash, $m Operating cash flow (3) (5) (10) (9) (11) (9) (12) (7) (7) (7)
Capex — 0 0 0 0 0 0 0 0 0
Free cash flow (3) (5) (10) (9) (11) (9) (13) (7) (7) (7)
Balance, $m
Balance, $m Working capital (5) 10 9 11 7 22 12 10 8 13
Total debt 26 4 — 0 0 0 0 — — —
Net debt 21 (8) (12) (15) (9) (25) (12) (11) (9) (15)
Shareholders’ equity (25) (32) 10 12 8 23 12 10 8 13
Returns, %
Returns, % ROA (12.26) (114.47) (77.42) (71.86) (84.89) (68.26) (66.84) (71.42) (90.20) (90.13)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE 4.22 39.42 96.11 (97.98) (115.46) (81.04) (76.17) (80.30) (103.34) (108.01)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2025

Charts ten years each

Entera Bio Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ASMB Assembly Biosciences, Inc. $479.1M 22.3× — (loss-making) +38.94% (above 0%: growing) n/m +7.58% (above 0%: growing) 100.00% (47.44%) Compare
YDES YD Bio Limited $476.8M — — — — — — — Compare
RZLT Rezolute, Inc. $471.1M — (loss-making) — — n/m +40.23% (above 0%: growing) 0.00% 0.00% Compare
ENTX Entera Bio Ltd. $462.4M — (loss-making) — (loss-making) +200.00% (above 0%: growing) n/m −108.86% (below 0%: shrinking) 0.00% 0.00%
TECX Tectonic Therapeutic, Inc. $456.1M — (loss-making) — — n/m −46.69% (below 0%: shrinking) 0.00% 0.00% Compare
CAPR Capricor Therapeutics, Inc. $455.2M — (loss-making) — (loss-making) −7.92% (below 0%: shrinking) n/m −72.88% (below 0%: shrinking) 100.00% 0.00% Compare
PRTA Prothena Corporation plc $453.8M — (loss-making) 188× −77.15% (below 0%: shrinking) n/m +44.64% (above 0%: growing) 100.00% (2,089.21%) Compare
DMAC DiaMedica Therapeutics, Inc. $449.2M — (loss-making) — (loss-making) — n/m −6.75% (below 0%: shrinking) 0.00% 0.00% Compare
EDIT Editas Medicine, Inc. $445.4M — (loss-making) — (loss-making) +232.31% (above 0%: growing) n/m +40.72% (above 0%: growing) 100.00% (156.05%) Compare
Median of peers $455.7M — — +15.51% — +7.58% 100.00% 0.00%

All 614 Biotechnology stocks →

Entera Bio Ltd. (ENTX) key facts

  • Concern: Entera Bio Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42,000.00, down 76.8% from fiscal 2024.
  • Entera Bio Ltd. (ENTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 12, 2026, ENTX traded at $2.65, a market capitalization of $460.7 million.
  • Return on equity was −108.0% and debt-to-equity 0.00.
  • Its Altman Z-score is 6.22 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Entera Bio Ltd. (ENTX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ENTX · Data as of Mar 31, 2025 · For information only; not investment advice. · © 2026 stockrow.com